Avaliação da Prevalência do HPV na População Portadora de Neoplasia Maligna de Região de Cabeça e Pescoço e o Status do p-16 por Imunohistoquímica Associado a Resposta Terapêutica

• Ano de defesa: 2018
• Autor(a) principal: Baldino, Leandro
• Orientador(a): Silva, Katia Luz Torres
• Banca de defesa: Fujimoto, Luciana Botinelly Mendonça , Ono, Lia Mizobe , Fonseca, Alex Jadim
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Amazonas
• Programa de Pós-Graduação: Programa de Pós-graduação em Ciências da Saúde
• Departamento: Instituto de Ciências Biológicas
• País: Brasil
• Palavras-chave em Português: Papilomavírus; Cabeça - Tumores - Radioterapia; Pescoço - Tumores - Radioterapia; Genes p16
• Área do conhecimento CNPq: CIÊNCIAS DA SAÚDE
• Link de acesso: https://tede.ufam.edu.br/handle/tede/7379

Human Papillomavirus (HPV) has long been related as the main cause of malignant neoplasia of the cervix. With the advancement of new diagnostic methods this virus has also been related to other cancers, such as penis, anal canal, prostate, lung and head and neck neoplasms. And in these cases of head and neck, the presence of HPV infection is related to the prognosis and treatment of the disease. In cavity neoplasms oral and oropharynx the relationship with HPV infection has already been established and stratification of these patients into virus-positive or non-virus-positive groups helps to promote better therapy and treatment response. This study aims to evaluate the prevalence of HPV 16 infection in patients with oral cavity neoplasia and oropharynx and stratify into groups according to P16 protein expression, relating to radiotherapy treatment offered to patients at FCECON treated from 2009 to 2013 and the response to treatment. Tissue was analyzed paraffin-embedded lesions of patients who were segregated according to the diagnosis of oral cavity and oropharynx neoplasia, in HPV positive or not groups 16. An analysis was made of the relationship between infection and response to therapy. proposal (radiotherapy and chemotherapy). In addition, patients were stratified in three groups according to P16 protein expression: HPV16-negative / P16 negative, HPV16 negative / P16 positive and HPV16 positive / P16 positive. Regarding 89.94% were male, the average age was 60.77 years, 64% had an oropharyngeal lesion and 36% had an oral cavity. Most of the patients (93.7%) were at an advanced stage. The prevalence was observed of 16.67% positivity for HPV16 infection and finally in P16 research 18.52% were positive. Only 3 patients attested positivity for both exams (HPV16 + and P16 +). The Routine Use of P16 Research by immunohistochemistry and HPV investigation of the lesion in all patients with diagnosis of oral cavity and oropharynx neoplasia should be implanted, taking into since there are changes in staging of these neoplasms when positive for HPV and improvement of therapeutic response.